Connaughton Bernadette's Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Sep 2, 2025
- Accession no.
- 0001415889-25-023470
- Filed
- Sep 2, 2025
- Trade date
- Sep 2, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $294.7K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Connaughton BernadetteCIK 0001662521 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2025 | Common Stock | SSaleDisposed | −100 | $71.71 | −$7,171 | 50,852 | Direct | |
| Sep 2, 2025 | Common Stock | SSaleDisposed | −2,977 | $73.62 | −$219,166.74 | 47,875 | Direct | |
| Sep 2, 2025 | Common Stock | SSaleDisposed | −923 | $74.11 | −$68,403.53 | 46,952 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.